Genedrive is a commercial stage personalised medicine and biotechnology company developing innovative diagnostics and biomarkers alongside providing contract research services to drug development companies.
Genedrive was founded as a contract research business (”CRO”) but is now refocussing as a Point of Care molecular diagnostics company. The company has developed and launched Genedrive®: a next-generation Point of Care molecular diagnostic system providing a low cost, rapid, versatile, simple to use and robust diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications.
With the rapid global shift of healthcare to testing and treatment of COVID-19, the company has refocused part of its resources to the development of two SARS-COV-2 tests.
The successful launch of Genedrive’s TB diagnosis system in India, the appointment of an extremely experienced CEO, David Budd, and significant advances in the development of point of care Hepatitis C diagnostic systems, are extremely encouraging to us as investors, pointing to important advances in Genedrive’s areas of medical diagnostics and a bright future for the business and its investors.
Genedrive (previously called Epistem) is quoted on the Alternative Investment Market (AIM). Calculus successfully exited a previous investment in Epistem in 2014 from its EIS funds.